Owners, management and financials
CVR: 40279865
Secondary names: Ciana Therapeutics ApS
Previous names: Visus Therapeutics ApS, Ciana Therapeutics ApS
DKK -7,655,438
Gross profit
Net result: DKK -85,575,302
Novo Holdings A/S (33,33-49,99%), Sound Bioventures Fund I AB (15-19,99%)
2 more
CVR · view owners
Ulrik Mouritzen
Board: Jimmy Arnold V Van Heusden (chair) and 6 members
CVR · view management
Active
Founded 13 February 2019
CVR · view overview
3 employees
CVR · 2026
Owner registered: Novo Holdings A/S
CVR · 24/09/2026
View the full event history
Breye Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ciana Therapeutics ApS and Visus Therapeutics ApS. The management consists of Ulrik Mouritzen. The board consists of Jimmy Arnold V Van Heusden (chair), Carl Johan Kördel, Gabriela Burian and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Sound Bioventures Fund I AB and Mission BioCapital VI LP. The company has 3 employees (2026). In 2026, the company reported a gross profit of DKK -7,655,438 and a net result of DKK -85,575,302 compared with DKK -89,139,846 the year before. Equity in the 2026 report amounted to DKK -126,213,092.
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202601/04/2025 – 31/03/2026 | -7.7 mio. | -85.6 mio. | 40.6 mio. | -126.2 mio. | 3 | |
| 202501/04/2024 – 31/03/2025 | -7.5 mio. | -89.1 mio. | 57 mio. | -40.6 mio. | 3 | |
| 202401/04/2023 – 31/03/2024 | -7.8 mio. | -70.2 mio. | 60.7 mio. | 48.5 mio. | 2 | |
| 202301/04/2022 – 31/03/2023 | -2.9 mio. | -14.6 mio. | 24.8 mio. | 14.5 mio. | 1 | |
| 202201/04/2021 – 31/03/2022 | -674 t. | -780 t. | 18.7 mio. | -752 t. | 1 | |
| 202101/04/2020 – 31/03/2021 | -68 t. | -290 t. | 14.2 mio. | 28 t. | 1 |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorThe CVR number of Breye Therapeutics ApS is 40279865.
The owners of Breye Therapeutics ApS include Novo Holdings A/S, Sound Bioventures Fund I AB and Mission BioCapital VI LP.
The management of Breye Therapeutics ApS consists of Ulrik Mouritzen.
The board of Breye Therapeutics ApS consists of Jimmy Arnold V Van Heusden, Carl Johan Kördel and Gabriela Burian, with Jimmy Arnold V Van Heusden as chair.
In 2026, Breye Therapeutics ApS reported a gross profit of DKK -7,655,438.
Breye Therapeutics ApS had 3 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Breye Therapeutics ApS has published its annual report for 2026. Gross profit came to DKK -7,655,438, and the net result was DKK -85,575,302.
As of September 24, 2026, Robert Glenn Blajez has joined the board of directors of Breye Therapeutics ApS.
As of September 24, 2026, Oskar Lukas Fredrik Ljungström has joined the board of directors of Breye Therapeutics ApS.
As of September 24, 2026, Chiara Rossana Maria Liberati has left the board of directors of Breye Therapeutics ApS.
As of September 24, 2026, Novo Holdings A/S is registered as an owner of Breye Therapeutics ApS with an ownership share of 33%.
As of September 24, 2026, is registered as an owner of Breye Therapeutics ApS with an ownership share of 15%.
As of September 24, 2026, is registered as an owner of Breye Therapeutics ApS with an ownership share of 5%.
As of September 24, 2026, is registered as an owner of Breye Therapeutics ApS with an ownership share of 5%.
Breye Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -7,545,558, and the net result was DKK -89,139,846.
Breye Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -7,812,131, and the net result was DKK -70,150,057.
Breye Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -2,882,747, and the net result was DKK -14,574,884.
As of June 6, 2023, Chiara Rossana Maria Liberati has joined the board of directors of Breye Therapeutics ApS.
As of December 5, 2022, Gabriela Burian has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, EY Godkendt Revisionspartnerselskab has been appointed auditor of Breye Therapeutics ApS.
As of November 4, 2022, EMIT P/S has stepped down as auditor of Breye Therapeutics ApS.
As of November 4, 2022, Jørgen Søberg Petersen has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Ulrik Mouritzen has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Carl Johan Kördel has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Jimmy Arnold V Van Heusden has joined the board of directors of Breye Therapeutics ApS.
On November 4, 2022, the company changed its name from Ciana Therapeutics ApS to Breye Therapeutics ApS.
Breye Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -673,849, and the net result was DKK -780,005.
Breye Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -67,528, and the net result was DKK -289,668.
As of October 29, 2020, EMIT P/S has been appointed auditor of Breye Therapeutics ApS.
On August 25, 2020, the company changed its name from Visus Therapeutics ApS to Ciana Therapeutics ApS.
Breye Therapeutics ApS has published its interim report for the period February 13, 2019 to March 31, 2020.
As of February 13, 2019, Ulrik Mouritzen is registered as adm. dir. of Breye Therapeutics ApS.
Breye Therapeutics ApS was founded on February 13, 2019.
Companies in the same industry and area
CVR 29526346
CVR 37728403
CVR 34623562
CVR 38445928
CVR 63717916
